Search

BACKGROUND: There is limited data on the adult repair of pectus excavatum (PE). Existing literature is largely limited to single institution experiences and suggests that adults undergoing modified Nuss repair may have worse outcomes than pediatric and adolescent patients. Using a representative national database, this analysis is the first to describe trends in demographics, outcomes, charges, and facility volume for adults undergoing modified Nuss procedure. METHODS: Because of a coding change associated with ICD-10, a retrospective cohort analysis using the National Inpatient Sample (NIS) for patients 12 or older undergoing modified Nuss repair between 2016–2018 was possible. Pearson’s χ(2) and Student’s t-tests were utilized to compare patient, clinical, and hospital characteristics. Complications were sub-classified into major and minor categories. Facilities performing greater than the mean number of operations were categorized as high-volume. RESULTS: Of 360 patients, 79.2% were male. There was near gender parity for patients over 30 undergoing repair (55.2% male, 44.8% female). In all age cohorts, patients were predominantly Caucasian. Rates of any postoperative complication differed by age (12–17 years: 30.6%; 18–29 years: 45.2%; 30+ years: 62.1%; P

Supplemental material, sj-docx-1-gut-10.1177_26345161231151407 for An Analysis of 30-Day Readmissions of Surgically Managed Hiatal Hernia in the United States, 2010 to 2018 by Gregory L. Whitehorn, Micaela L. Collins, Shale J. Mack, Brian M. Till, Christina J. Tofani, Karen A. Chojnacki and Olugbenga T. Okusanya in Foregut: The Journal of the American Foregut Society

Supplemental material, sj-docx-1-gut-10.1177_26345161231151407 for An Analysis of 30-Day Readmissions of Surgically Managed Hiatal Hernia in the United States, 2010 to 2018 by Gregory L. Whitehorn, Micaela L. Collins, Shale J. Mack, Brian M. Till, Christina J. Tofani, Karen A. Chojnacki and Olugbenga T. Okusanya in Foregut: The Journal of the American Foregut Society

Supplemental material, sj-pptx-1-gut-10.1177_26345161221137089 for The Epidemiology of Surgically Managed Hiatal Hernia: A Nine Year Review of National Trends by Brian M. Till, Shale J. Mack, Gregory Whitehorn, Micaela Langille Collins, Chi-Fu Jeffrey Yang, Tyler Grenda, Nathaniel R. Evans and Olubenga Okusanya in Foregut: The Journal of the American Foregut Society

Supplemental material, sj-docx-1-gut-10.1177_26345161221137089 for The Epidemiology of Surgically Managed Hiatal Hernia: A Nine Year Review of National Trends by Brian M. Till, Shale J. Mack, Gregory Whitehorn, Micaela Langille Collins, Chi-Fu Jeffrey Yang, Tyler Grenda, Nathaniel R. Evans and Olubenga Okusanya in Foregut: The Journal of the American Foregut Society

Supplemental material, sj-pptx-3-gut-10.1177_26345161221091205 for Does Age Impact Risk of Morbidity and Mortality for Elective Paraesophageal Hernia Repair in the Era of Minimally-Invasive Repair? by Shale J. Mack, Brian M. Till, Darshak Thosani, Uzma Rahman, Stephanie G. Worrell, Tyler Grenda, Nathaniel R. Evans and Olugbenga T. Okusanya in Foregut: The Journal of the American Foregut Society

Supplemental material, sj-docx-2-gut-10.1177_26345161221091205 for Does Age Impact Risk of Morbidity and Mortality for Elective Paraesophageal Hernia Repair in the Era of Minimally-Invasive Repair? by Shale J. Mack, Brian M. Till, Darshak Thosani, Uzma Rahman, Stephanie G. Worrell, Tyler Grenda, Nathaniel R. Evans and Olugbenga T. Okusanya in Foregut: The Journal of the American Foregut Society

Supplemental material, sj-docx-1-gut-10.1177_26345161221091205 for Does Age Impact Risk of Morbidity and Mortality for Elective Paraesophageal Hernia Repair in the Era of Minimally-Invasive Repair? by Shale J. Mack, Brian M. Till, Darshak Thosani, Uzma Rahman, Stephanie G. Worrell, Tyler Grenda, Nathaniel R. Evans and Olugbenga T. Okusanya in Foregut: The Journal of the American Foregut Society

Supplemental material, sj-docx-2-gut-10.1177_26345161221091205 for Does Age Impact Risk of Morbidity and Mortality for Elective Paraesophageal Hernia Repair in the Era of Minimally-Invasive Repair? by Shale J. Mack, Brian M. Till, Darshak Thosani, Uzma Rahman, Stephanie G. Worrell, Tyler Grenda, Nathaniel R. Evans and Olugbenga T. Okusanya in Foregut: The Journal of the American Foregut Society

Supplemental material, sj-docx-1-gut-10.1177_26345161221091205 for Does Age Impact Risk of Morbidity and Mortality for Elective Paraesophageal Hernia Repair in the Era of Minimally-Invasive Repair? by Shale J. Mack, Brian M. Till, Darshak Thosani, Uzma Rahman, Stephanie G. Worrell, Tyler Grenda, Nathaniel R. Evans and Olugbenga T. Okusanya in Foregut: The Journal of the American Foregut Society

Relapsed or refractory classical Hodgkin lymphoma could be treated with multiagent salvage chemotherapy followed by autologous haematopoietic stem-cell transplantation. The aim of this study is to establish the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide, carboplatin, and etoposide (BV-ICE) chemotherapy in second-line treatment of classical Hodgkin lymphoma.We conducted a single-arm, open-label, phase 1/2 study of dose-dense BV-ICE at the Seattle Cancer Care Alliance, University of Washington (Seattle, WA, USA). Eligibility criteria were age 18 years or older; diagnosis of first relapse, primary refractory classical Hodgkin lymphoma after one previous line of therapy; measurable disease of at least 1 cm in the longest axis, CT of chest, abdomen, and pelvis with PET within the past 28 days; Eastern Cooperative Oncology Group performance status of 0-1; and adequate organ function. A 3 + 3 dose escalation study was done for the phase 1 part of the trial to establish the maximum tolerated dose to be used for the phase 2 study. Brentuximab vedotin was delivered on days 1 and 8 at either 1·2 mg/kg (dose level 1) or 1·5 mg/kg (dose level 2) intravenously (capped at 150 mg) with standard dosing of ICE on days 1-3 (ifosfamide 5 g/mBetween Oct 16, 2014, and Feb 10, 2020, we enrolled 45 patients with a median age of 31 years (IQR 28-45). The recommended phase 2 dose of brentuximab vedotin was established to be 1·5 mg/kg. After a median follow-up of 3·1 years (IQR 1·7-4·1), 32 (74%; 95% CI 58·8-86·5) of 43 evaluable patients had complete responses after two cycles of treatment. Grade 3-4 haematological toxic effects were common, including neutropenia (33 [73%]), anaemia (six [13%]), and thrombocytopenia (36 [80%]). The most common grade 3-4 non-haematological toxic effects were febrile neutropenia (four [9%]), sepsis (six [13%]), increased alanine aminotransferase (five [11%]), hyperglycaemia (three [7%]), pulmonary embolism (two [4%]), and increased aspartate aminotransferase (two [4%]). There was one (2%) on-treatment death due to multisystem organ failure that was considered treatment related. Serious adverse events occurred in 13 (29%) patients.Our data suggest that dose-dense BV-ICE is a rapidly administered and active salvage regimen for patients with relapsed or refractory classical Hodgkin lymphoma despite a complete response in this trial lower than the prespecified phase 2 target. Although cross-trial comparisons should be made with caution, activity results seem to be similar to previously presented brentuximab vedotin chemotherapy salvage combinations delivered over much longer durations and can be considered in young (60 years), transplantation-eligible patients for second-line therapy.Seagen, Lymphoma Research Foundation, National Institutes of Health/National Cancer Institute, and generous philanthropic donations to the University of Washington from numerous individuals and families in support of lymphoma research.

Autologous stem cell transplantation (ASCT) is standard therapy for mantle cell lymphoma (MCL) in remission after induction chemotherapy, with the best results for patients in complete remission (CR). We hypothesized that evaluation of minimal residual disease (MRD) before ASCT could further stratify outcomes for these patients. Patients with MCL who underwent ASCT in clinical CR between 1996 and 2011 with pretransplantation MRD testing were eligible. Presence of a clonal IgH rearrangement, t(11; 14) by PCR or positive flow cytometry from blood or bone marrow, was considered positive. An adjusted proportional hazards model for associations with progression-free (PFS) and overall survival (OS) was performed. Of 75 MCL patients in CR, 8 (11%) were MRD positive. MRD positivity was associated with shorter OS and PFS. The median OS for MRD-negative patients was not reached, with 82% survival at 5 years, whereas for the MRD-positive patients, median OS was 3.01 years (hazard ratio [HR], 4.04; P = .009), with a median follow-up of 5.1 years. The median PFS for MRD-negative patients was not reached with 75% PFS at 5 years, whereas for MRD-positive patients, it was 2.38 years (HR, 3.69; P = .002). MRD positivity is independently associated with poor outcomes after ASCT for MCL patients in CR.

Normalization of fluorodeoxyglucose positron emission tomography (FDG PET) imaging prior to high-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes in relapsed and refractory (RR) Hodgkin lymphoma (HL), but many patients refractory to platinum-based salvage regimens are unable to achieve this goal. We therefore investigated whether brentuximab vedotin (BV) could normalize FDG PET in platinum-refractory HL prior to ASCT. Fifteen consecutive patients with RR HL and FDG PET positive disease after platinum-based salvage therapy were treated with a median of 4 cycles of BV. Normalization of FDG PET (Deauville ≤2) occurred in 8/15 (53%) patients but was only observed in patients that had achieved partial remission or stable disease after platinum-based salvage therapy. All patients eventually proceeded to ASCT, regardless of FDG PET status. Our data suggest that BV can normalize FDG PET in a subset of patients with platinum-refractory HL prior to ASCT.